COVID-19PASC24NCT06298006
A Two Year Longitudinal Clinical Study of Neurocognitive and Psychiatric Symptoms in Post COVID-19 Patients
An observational study of COVID-19, run by Region Örebro County at 1 site in Sweden.
Trial summary
The prospective, longitudinal, open observational study monitors patients with cognitive and neuropsychological symptoms after COVID-19 infection, in a longitudinal manner to see how the disease has affected their physical, psychological and cognitive function, their ability to be active, return to work, their… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19
- What is being tested?
- Follow-up
- How many people
- 57 participants
- Where
- 1 siteSweden
- Study dates
- 22 Feb 2022to 30 Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The patients: * who have been referred for neurocognitive symptoms after Covid-19 infection to secondary health care at Örebro University Hospital (USÖ) or who themselves sought assessment at USÖ * who meet inclusion criteria and do not meet exclusion criteria * who agreed to study participation with a written informed consent.
Who may be able to join
- neurocognitive symptoms after lab-verified COVID-19 infection
Who cannot join
- severe illness e.g cancer with a short expected survival time
- ongoing alcohol abuse
- ongoing drug abuse.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Uppföljning av Psykiatriska, Kognitiva Och Neurologiska Symtom Hos Post COVID-19 Patienter.
The prospective, longitudinal, open observational study monitors patients with cognitive and neuropsychological symptoms after COVID-19 infection, in a longitudinal manner to see how the disease has affected their physical, psychological and cognitive function, their ability to be active, return to work, their health-related quality of life in correlation with potential diagnostic and prognostic markers.
Read the detailed description
The aim is to increase knowledge of the underlying biological processes; how biomarkers correlate with degree of symptoms, mapping their role as diagnostic markers over time (24 months).
The investigators follow up to 100 study participants with post-acute sequelae of SARS-CoV-2 infection (PASC) for 24 months, measure their physical, psychological and neurocognitive symtoms and how they change over time (three visits: baseline, 12 months, 24 months) in correlation with biomarkers in blood, cerebrospinal fluid and faeces samples as well as neuroradiological changes on MRI (baseline, 24 months).
Knowledge about the late effects of COVID-19 and its pathogenesis is still unknown. The findings of the study can therefore be used as a guidance for future actions in healthcare and, in the best case, can lead to a possible, either curative or symptom-relieving, treatment.
- Conditions
- COVID-19
- Being tested
- Follow-up
- Keywords
- COVID-19 sequelae, cognitive symptoms, neuropsychological symptoms, neuropsychological testing, biomarkers, cerebrospinal fluid, microbiota
- Medical subject headings
- COVID-19, Neurobehavioral Manifestations
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Follow-upOther
Follow-up of neurocognitive and psychiatric symptoms in Post COVID patients (baseline, 12 months, 24 months) in correlation with biomarkers using MRI, fMRI, neuropsychological testing, lab samples (blood, CSF, microbiota).
| Study group | Role | What they receive |
|---|---|---|
| PASC24 study participants | Patients with residual cognitive and psychiatric symptoms after COVID-19 infection who undergo follow-up. Receives: Other: Follow-up |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in cognitive functions measured with Mindmore and change in cognitive profile in Mindmore.
Two digital neurocognitive test batteries (Mindmore): dementia and fatigue/depression
Measured: baseline, 12 months, 24 months
Symptom improvement in depression
Montgomery Asberg Depression Rating Scale (MADRS) has has 10 items that are completed during a clinical interview.. The items of the MADRS are as follows: apparent sadness, reported sadness inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thought, suicidal thoughts.
MADRS assess the severity of depression. The severity of symptoms is rated by the physician. Each item has a severity scale from 0 to 6, with higher scores reflecting more severe symptoms. Ratings can be added to form an overall score (from 0 to 60) and the higher score means a worse outcome.
Measured: baseline, 12 months, 24 months
Self-reported symptom improvement in depression
Montgomery Asberg Depression Rating Scale, Self-report version (MADRS-S) has 9-items which are based on feelings over the past 3 days. The items of the MADRS-S are as follows: Mood; Feelings of unease; Sleep; Appetite; Ability to concentrate; Initiative; Emotional involvement; Pessimism; Zest for life.
MADRS-S assess the severity of depression. The severity of symptoms is rated by the study participant. Each item has a severity scale from 0 to 6, with higher scores reflecting more severe symptoms. Ratings can be added to form an overall score (from 0 to 54) and the higher score means a worse outcome.
Measured: baseline, 12 months, 24 months
Grade of self-reported mental fatigue
The Mental Fatigue scale (MFS) includes 14 questions that measure mental fatigue. Questions include affective, cognitive and sensory symptoms, duration of sleep and daytime variation in symptom severity. The questions concern fatigue in general, lack of initiative, mental fatigue, mental recovery, concentration difficulties, memory problems, slowness of thinking, sensitivity to stress, increased tendency to become emotional, irritability, sensitivity to light and noise, decreased or increased sleep. One additional question includes 24-hour symptom variations. The severity of symptoms is rated by the study participant. A rating of 0 corresponds to normal function and 1-3 indicating increasing problem with the symptom (No (0), Slight (1), Fairly serious (2) and Serious (3) problems). Ratings can be added to form an overall score (from 0 to 42) and the higher score means a worse outcome.
Measured: baseline, 12 months, 24 months
Rate of self-reported symptoms suggestive of post-traumatic stress disorder (PTSD)
The Post-traumatic Stress Disorder Checklist for The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, DSM-5 (PCL-5) is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD.
The study partipicipant answer first a brief Criterion A för PTSD. If the answer is affirmative (i.e. PTSD is suspected) the participants continue with 20 questions (items). Each item is rated from 0 ("not at all") to 4 ("extremely") to indicate the degree to which they have been bothered by that particular symptom over the past month. Ratings can be added to form an overall score (from 0 to 80) and the higher score means a worse outcome.
Measured: baseline, 12 months, 24 months
Grade of self-reported stress
Th Perceived Stress Scale (PSS-14) is a self-reported measure which assesses the degree to which the respondent has perceived situations in his/her life within the past month as stressful.
The PSS-14 is comprised of 14 items intended to measure how unpredictable, uncontrollable, and overloaded individuals find their life circumstances. Individuals rate items on a 5-point Likert scale, ranging from 0 - "Never" to 4 - "Very often." Scores range from 0-56, with higher scores indicating greater perceived stress.
Measured: baseline, 12 months, 24 months
Grade of self-reported cognitive failures in everyday life
The cognitive Failures Questionnaire (CFQ) is a self-report questionnaire consisting of 25 items assessing deficits regarding attention, perception, memory and motor functioning in everyday life. The total CFQ score is calculated by summation of all answers and scores range from 0-100. A higher total score indicates more subjective cognitive failure.
Measured: baseline, 12 months, 24 months
Secondary outcomes (17)
Occurence of activity limitations and changes in health-related quality of life (QoL)
Rating scale: the EuroQol-5 Dimension, 5 levels (EQ-5D-5L) with EuroQol-visual analogue scale (EQ-VAS)
EQ-5D-5L assesses the current state of health in five dimensions related to well-being and function; mobility, personal care, regular activities, pain/discomfort and anxiety/depression. Each dimension has five levels from "No problems" to "extreme problems". This results in a single-digit number (from 1 to 5) that expresses the level selected for that dimension. Higher digits/scores mean en worse uotcome.
EQ-VAS registers the patient's self-rated health in a analog scale with the minimum and maximum values: 0-100 where the endpoints are marked: 100 -"The best health you can imagine" and 0 - "The worst health you can imagine". Lower scores mean a worse outcome.
Measured: baseline, 12 months, 24 months
Grade of work incapacity/sick leave and time to return to work
Self-assessment questionnaire.
Study participant report grade of eventual sick-leave. According to Swedish legislation, four degrees of sick leave are possible (25%, 50%, 75%, 100%), where a higher number of percentages means worse outcome i.e. more reduced ability to work.
They also report the time of incapacity for work (number of months of sick leave (1- 100)) where higher numbers mean worse outcome i.e. longer time of incapacity for work
Measured: baseline, 12 months, 24 months
Changes in body size
Body mass index (BMI) gives an indication of the body size. Along with several other factors, BMI can help estimate the risk of a cardiovascular disease.
BMI is calculated using weight and height. BMI Categories: Underweight = <18.5, Normal weight = 18.5-24.9, overweight = 25-29.9, obesity = BMI of 30 or greater. The values under 18.5 and over 25 indicate worse outcome.
Measured: baseline, 12 months, 24 months
Waist size
The waist measurement is an indicator of the abdominal obesity that is associated with an increased risk of type 2 diabetes, cardiovascular disease and death, The values over 94cm for men and over 80cm for women indicate worse outcome i.e. abdominal obesity.
Measured: baseline, 12 months, 24 months
Rate of peak expiratory flow (PEF)
PEF rate is the volume of air forcefully expelled from the lungs in one quick exhalation, and is an indicator of ventilation adequacy as well as airflow obstruction. Air flow is measured with the portable, hand-held device. Three readingss are performed ond the highest of three readings is used as the recorded value of the PEF Rate. PEF is measured in units of liters per minute (0-800). The expected value depends on the participant's sex, age, and height but higher numbers in the given study participant mean better outcome i.e. better lung function.
Measured: baseline, 12 months, 24 months
Grade of physical exercise capacity
60 Second Sit-to-Stand Test (60STS) gives a measure of exercise capacity. The participant is encouraged to complete as many full stands as possible within 60 seconds. The number of full stands is registered (0-100) where higher numbers mean better outcome i.e. better physical fitness.
Measured: baseline, 12 months, 24 months
Concetration of Beta-Amyloid 42 in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration.
Beta-amyloid 40 and 42 are formed from amyloid precursor protein (APP) and are normally transported to the cerebrospinal fluid (CSF). In Alzheimer's disease, Beta-amyloid 42 accumulates in senile plaque and thus the level falls in CSF. Slightly lower levels of beta-amyloid 42 can also be seen in other dementia diseases.
Cerebrospinal fluid will be collected by trained physician and results will be reported as ng/L. The expected value depends on the participant's age, but lower values in the given study participant mean worse outcome i.e. more possible neurodegeneration.
Measured: baseline, 24 months
Beta Amyloid Ratio 42/40 in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration linked to Alzheimer's disease
Beta amyloid 40 is the most common variant of beta amyloid in CSF, while beta amyloid 42 predominates in senile plaques . Decreased ratio of Beta amyloid 42/40 is a strong marker of Alzheimer's disease and can be detected early in the disease progression, even before clinical dementia occurs.
Cerebrospinal fluid will be collected by trained physician and the result is reported as a ratio. Reference interval: > 0.72 ( > 50 years of age). Lower ratio means worse outcome i.e. possible Alzheimer's disease.
Measured: baseline, 24 months
Concentration of neurogranin in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration linked to Alzheimer's disease
Neurogranin is a protein expressed in synapses of the pyramidal cells of the hippocampus and cortex. Neurogranin is elevated in cerebrospinal fluid from individuals with Alzheimer's disease, but not from healthy individuals or individuals with other neurodegenerative diseases.
Cerebrospinal fluid will be collected by trained physician and results will be reported as ng/L. The expected value depends on the participant's age, but higher values in the given study participant mean worse outcome i.e. more possible neurodegeneration.
Measured: baseline, 24 months
Concentration of Tau (P-Tau) protein in cerebrospinal fluid (CSF) as a CSF biomarker of cortikal damage/neurodegeneration
Tau protein is a recognized biomarker of cortical damage and is assumed to be a nonspecific marker of neurodegeneration.
Cerebrospinal fluid will be collected by trained physician and results will be reported as ng/L. The expected value depends on the participant's age, but higher values in the given study participant mean worse outcome i.e. more possible cortical damage/neurodegeneration.
Measured: baseline, 24 months
Concentration of phosphorylated Tau (P-Tau) in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration/taupathy
Under physiological conditions, tau protein regulates the assembly and maintenance of the structural stability of microtubules in nerve cells. In certain brain diseases tau proteine becomes abnormally hyperphosphorylated, which ultimately causes the microtubules to disassemble, and the free tau molecules aggregate into paired helical filaments.
Phosphorylated tau (P-tau) is assumed to be a relatively specific marker for Alzheimers disease because neurofibrillary tangles that är found in AD patients primarily consist of tau protein in the abnormally hyperphosphorylated state
Cerebrospinal fluid will be collected by trained physician and results will be reported as ng/L. The expected value depends on the participant's age, but higher values in the given study participant mean worse outcome i.e. more possible neurodegeneration.
Measured: baseline, 24 months
Concentration of neurofilament light (NFL) in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration
Neurofilament light (NFL) is a recognized biomarker of subcortical large-caliber axonal degeneration and is assumed to be a nonspecific marker of neurodegeneration.
Cerebrospinal fluid will be collected by trained physician and results will be reported as ng/L. The expected value depends on the participant's age, but higher values in the given study participant mean worse outcome i.e. more possible neurodegeneration.
Measured: baseline, 24 months
Concentration of neurofilament light (NFL) in plasma as a blood biomarker of neurodegeneration
Blood-based biomarkers of neurodegeneration have obvious advantages over both CSF and neuroimaging biomarkers. The collection of blood is inexpensive, noninvasive, and a more feasible measure for use in the general population, especially if serial collection is needed. Neurofilament light (NFL) is a recognized biomarker of subcortical large-caliber axonal degeneration and is assumed to be a nonspecific marker of neurodegeneration.
Plasma will be collected by trained personnel and results will be reported as ng/L. The expected value depends on the participant's age, but higher values in the given study participant mean worse outcome i.e. more possible neurodegeneration. The values will be also compared with NFL values in cerebrospinal fluid (outcome 20), which are still the "golden standard" of NFL measurement
Measured: baseline, 24 months
Occurence of APOE4 allele as biomarker of genetic predisposition to Alzheimer's disease and susceptibility to more severe course of COVID-19 infection
The human APOE gene exists as three polymorphic alleles-ε2, ε3 and ε4-which have a worldwide frequency of 8.4%, 77.9% and 13.7%, respectively. However, the frequency of the ε4 allele is dramatically increased to ~40% in patients with late onset Alzheimers disease. APOE4 allele has also been correlated with severe COVID-19 outcomes.
Plasma will be collected by trained personnel and results will be reported as combination of two alleles with six possible alternatives: 2/2, 2/3, 2/4, 3/3, 3/4, 4/4. Alternatives with the APOE4 allele indicate worse outcomes and combinationen: 4/4 indicates the worst possible outcome.
Measured: baseline
Brain volumes and signal abnormalities in white and gray matter
Imaging of the brain using Magnetic Resonance Imaging (MRI) scans. The scans are compared over time to assess changes of brain volume and progress/regression of signal abnormalities/lesions in gray and white matter
Measured: baseline, 24 months
Changes in functional and structural brain connectivity
Imaging of the brain activity at rest using resting-state functional Magnetic Resonance Imaging (rs-fMRI). Rs-fMRI measures spontaneous low-frequency fluctuations in the BOLD signal to investigate the functional architecture of the brain and to identify various resting-state networks (RSN). The scans are compared over time to detect changes in functional and structural connectivity of the brain.
Measured: baseline, 24 months
Changes in gut microbiome
The gut microbiome in COVID-19 is characterized by increased fecal fungal load and increased beta-diversity (more heterogeneous), and it is unstable over time and also persistently altered after disease resolution. Assessment of gut microbiome as well as changes over time will be carried out via analysis of the fecal samples for microbial composition using 16S microbiome analysis, metabolomics and Next Generation Sequencing.
Measured: Baseline, 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2024
- Study start22 Feb 2022
- Primary completion31 May 2026 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 57 participants (actual)
Sponsor and investigators
- Lead sponsor
- Region Örebro County
- Sponsor type
- University, hospital or other
- Collaborators
- Örebro University, Sweden, Karolinska Institutet, Karolinska University Hospital, Sahlgrenska University Hospital
- Responsible party
- Sponsor
- Investigators
- Yvonne Freund-Levi, MD, PhD, Principal investigator, Medical Faculty, Örebro University, Dept of Geriatrics, USÖ
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06298006
- Sponsor's protocol ID
- 275025
- Acronym
- PASC24
- Status last verified
- Jan 2025
- First submitted
- 17 Jan 2024
- Last updated
- 11 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
van den Hurk W, Bergman I, Machado A, Bjermo J, Gustavsson A. Swedish Normative Data for Mindmore: A Comprehensive Cognitive Screening Battery, Both Digital and Self-Administrated. J Int Neuropsychol Soc. 2022 Feb;28(2):188-202. doi: 10.1017/S135561772100045X. Epub 2021 May 24.
PubMed 34027854Meehan A, Dzialanski Z, Hjelmqvist H, Julin P, Thunberg P, Freund-Levi Y. Neurocognitive and psychological symptoms in post COVID-19 patients (PASC24): prospective cohort study protocol. BMJ Open. 2026 Jul 17;16(7):e116689. doi: 10.1136/bmjopen-2026-116689.
PubMed 42468962
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Uppföljning av Psykiatriska, Kognitiva Och Neurologiska Symtom Hos Post COVID-19 Patienter.
- ClinicalTrials.gov ID
- NCT06298006
- Acronym / sponsor ID
- PASC24 / 275025
- Conditions
- COVID-19
- Keywords
- COVID-19 sequelae, cognitive symptoms, neuropsychological symptoms, neuropsychological testing, biomarkers, cerebrospinal fluid, microbiota
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 57 participants (actual)
- Lead sponsor
- Region Örebro CountyUniversity, hospital or other
- Collaborators
- Örebro University, Sweden, Karolinska Institutet, Karolinska University Hospital, Sahlgrenska University Hospital
- Study start
- 22 Feb 2022 (actual)
- Primary completion
- 31 May 2026 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 7 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The prospective, longitudinal, open observational study monitors patients with cognitive and neuropsychological symptoms after COVID-19 infection, in a longitudinal manner to see how the disease has affected their physical, psychological and cognitive function, their ability to be active, return to work, their health-related quality of life in correlation with potential diagnostic and prognostic markers.
Detailed description
The aim is to increase knowledge of the underlying biological processes; how biomarkers correlate with degree of symptoms, mapping their role as diagnostic markers over time (24 months).
The investigators follow up to 100 study participants with post-acute sequelae of SARS-CoV-2 infection (PASC) for 24 months, measure their physical, psychological and neurocognitive symtoms and how they change over time (three visits: baseline, 12 months, 24 months) in correlation with biomarkers in blood, cerebrospinal fluid and faeces samples as well as neuroradiological changes on MRI (baseline, 24 months).
Knowledge about the late effects of COVID-19 and its pathogenesis is still unknown. The findings of the study can therefore be used as a guidance for future actions in healthcare and, in the best case, can lead to a possible, either curative or symptom-relieving, treatment.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| PASC24 study participants | – | Other: Follow-upPatients with residual cognitive and psychiatric symptoms after COVID-19 infection who undergo follow-up. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The patients: * who have been referred for neurocognitive symptoms after Covid-19 infection to secondary health care at Örebro University Hospital (USÖ) or who themselves sought assessment at USÖ * who meet inclusion criteria and do not meet exclusion criteria * who agreed to study participation with a written informed consent.
Key inclusion criteria (1 listed)
- neurocognitive symptoms after lab-verified COVID-19 infection
Key exclusion criteria (3 listed)
- severe illness e.g cancer with a short expected survival time
- ongoing alcohol abuse
- ongoing drug abuse.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Follow-upFollow-up of neurocognitive and psychiatric symptoms in Post COVID patients (baseline, 12 months, 24 months) in correlation with biomarkers using MRI, fMRI, neuropsychological testing, lab samples (blood, CSF, microbiota). | Other | PASC24 study participants |
Primary outcome
Change in cognitive functions measured with Mindmore and change in cognitive profile in Mindmore.
Time frame: baseline, 12 months, 24 months
Two digital neurocognitive test batteries (Mindmore): dementia and fatigue/depression
Symptom improvement in depression
Time frame: baseline, 12 months, 24 months
Montgomery Asberg Depression Rating Scale (MADRS) has has 10 items that are completed during a clinical interview.. The items of the MADRS are as follows: apparent sadness, reported sadness inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thought, suicidal thoughts. MADRS assess the severity of depression. The severity of symptoms is rated by the physician. Each item has a severity scale from 0 to 6, with higher scores reflecting more severe symptoms. Ratings can be added to form an overall score (from 0 to 60) and the higher score means a worse outcome.
Self-reported symptom improvement in depression
Time frame: baseline, 12 months, 24 months
Montgomery Asberg Depression Rating Scale, Self-report version (MADRS-S) has 9-items which are based on feelings over the past 3 days. The items of the MADRS-S are as follows: Mood; Feelings of unease; Sleep; Appetite; Ability to concentrate; Initiative; Emotional involvement; Pessimism; Zest for life. MADRS-S assess the severity of depression. The severity of symptoms is rated by the study participant. Each item has a severity scale from 0 to 6, with higher scores reflecting more severe symptoms. Ratings can be added to form an overall score (from 0 to 54) and the higher score means a worse outcome.
Grade of self-reported mental fatigue
Time frame: baseline, 12 months, 24 months
The Mental Fatigue scale (MFS) includes 14 questions that measure mental fatigue. Questions include affective, cognitive and sensory symptoms, duration of sleep and daytime variation in symptom severity. The questions concern fatigue in general, lack of initiative, mental fatigue, mental recovery, concentration difficulties, memory problems, slowness of thinking, sensitivity to stress, increased tendency to become emotional, irritability, sensitivity to light and noise, decreased or increased sleep. One additional question includes 24-hour symptom variations. The severity of symptoms is rated by the study participant. A rating of 0 corresponds to normal function and 1-3 indicating increasing problem with the symptom (No (0), Slight (1), Fairly serious (2) and Serious (3) problems). Ratings can be added to form an overall score (from 0 to 42) and the higher score means a worse outcome.
Rate of self-reported symptoms suggestive of post-traumatic stress disorder (PTSD)
Time frame: baseline, 12 months, 24 months
The Post-traumatic Stress Disorder Checklist for The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, DSM-5 (PCL-5) is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. The study partipicipant answer first a brief Criterion A för PTSD. If the answer is affirmative (i.e. PTSD is suspected) the participants continue with 20 questions (items). Each item is rated from 0 ("not at all") to 4 ("extremely") to indicate the degree to which they have been bothered by that particular symptom over the past month. Ratings can be added to form an overall score (from 0 to 80) and the higher score means a worse outcome.
Grade of self-reported stress
Time frame: baseline, 12 months, 24 months
Th Perceived Stress Scale (PSS-14) is a self-reported measure which assesses the degree to which the respondent has perceived situations in his/her life within the past month as stressful. The PSS-14 is comprised of 14 items intended to measure how unpredictable, uncontrollable, and overloaded individuals find their life circumstances. Individuals rate items on a 5-point Likert scale, ranging from 0 - "Never" to 4 - "Very often." Scores range from 0-56, with higher scores indicating greater perceived stress.
Grade of self-reported cognitive failures in everyday life
Time frame: baseline, 12 months, 24 months
The cognitive Failures Questionnaire (CFQ) is a self-report questionnaire consisting of 25 items assessing deficits regarding attention, perception, memory and motor functioning in everyday life. The total CFQ score is calculated by summation of all answers and scores range from 0-100. A higher total score indicates more subjective cognitive failure.
17 secondary outcomes
Occurence of activity limitations and changes in health-related quality of life (QoL)
Time frame: baseline, 12 months, 24 months
Grade of work incapacity/sick leave and time to return to work
Time frame: baseline, 12 months, 24 months
Changes in body size
Time frame: baseline, 12 months, 24 months
Waist size
Time frame: baseline, 12 months, 24 months
Rate of peak expiratory flow (PEF)
Time frame: baseline, 12 months, 24 months
Grade of physical exercise capacity
Time frame: baseline, 12 months, 24 months
Concetration of Beta-Amyloid 42 in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration.
Time frame: baseline, 24 months
Beta Amyloid Ratio 42/40 in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration linked to Alzheimer's disease
Time frame: baseline, 24 months
Concentration of neurogranin in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration linked to Alzheimer's disease
Time frame: baseline, 24 months
Concentration of Tau (P-Tau) protein in cerebrospinal fluid (CSF) as a CSF biomarker of cortikal damage/neurodegeneration
Time frame: baseline, 24 months
Concentration of phosphorylated Tau (P-Tau) in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration/taupathy
Time frame: baseline, 24 months
Concentration of neurofilament light (NFL) in cerebrospinal fluid (CSF) as a CSF biomarker of neurodegeneration
Time frame: baseline, 24 months
Concentration of neurofilament light (NFL) in plasma as a blood biomarker of neurodegeneration
Time frame: baseline, 24 months
Occurence of APOE4 allele as biomarker of genetic predisposition to Alzheimer's disease and susceptibility to more severe course of COVID-19 infection
Time frame: baseline
Brain volumes and signal abnormalities in white and gray matter
Time frame: baseline, 24 months
Changes in functional and structural brain connectivity
Time frame: baseline, 24 months
Changes in gut microbiome
Time frame: Baseline, 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2025.
- Background: PubMed 34027854van den Hurk W, Bergman I, Machado A, Bjermo J, Gustavsson A. Swedish Normative Data for Mindmore: A Comprehensive Cognitive Screening Battery, Both Digital and Self-Administrated. J Int Neuropsychol Soc. 2022 Feb;28(2):188-202. doi: 10.1017/S135561772100045X. Epub 2021 May 24.
- Derived from this study: PubMed 42468962Meehan A, Dzialanski Z, Hjelmqvist H, Julin P, Thunberg P, Freund-Levi Y. Neurocognitive and psychological symptoms in post COVID-19 patients (PASC24): prospective cohort study protocol. BMJ Open. 2026 Jul 17;16(7):e116689. doi: 10.1136/bmjopen-2026-116689.
- Information about the study on Örebro University's websiteLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yvonne Freund-Levi, MD, PhD principal investigator
Medical Faculty, Örebro University, Dept of Geriatrics, USÖ
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19, run by Region Örebro County at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 11 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in cognitive functions measured with Mindmore and change in cognitive profile in Mindmore. (time frame: baseline, 12 months, 24 months). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06298006, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2025.